Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges
- PMID: 15281906
- DOI: 10.2174/1568011043352885
Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges
Abstract
Antitumor agents targeting DNA and DNA-associated processes are widely used in the treatment of human cancers and produce significant increases in the survival of patients. DNA topoisomerases remain the most significant target of these cytotoxic drugs and constitute a growing family of nuclear enzymes that regulate DNA topology during DNA replication and recombination, DNA transcription, chromosome condensation-decondensation and segregation. Major progress has been attained in recent years in the understanding of the structures of these enzymes and their main cellular functions, hopefully providing new opportunities for pharmacological interventions. New leads and derivatives of known structures have been reported recently, and here they will be discussed highlighting the challenges to find innovative and more effective drugs. Moreover, we will review novel and diverse approaches relevant to the development of new topoisomerase-related therapeutics.
Similar articles
-
DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.Curr Med Chem Anticancer Agents. 2001 May;1(1):1-25. doi: 10.2174/1568011013354859. Curr Med Chem Anticancer Agents. 2001. PMID: 12678768 Review.
-
DNA topoisomerase i as a transcription protein and a lethal cellular toxin.Ital J Biochem. 2007 Jun;56(2):122-9. Ital J Biochem. 2007. PMID: 17722653 Review.
-
DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.Curr Opin Investig Drugs. 2002 Oct;3(10):1512-6. Curr Opin Investig Drugs. 2002. PMID: 12431029 Review.
-
Topoisomerase I-mediated DNA damage.Adv Cancer Res. 2001;80:189-216. doi: 10.1016/s0065-230x(01)80016-6. Adv Cancer Res. 2001. PMID: 11034544 Review.
-
Topoisomerase I inhibitors: camptothecins and beyond.Nat Rev Cancer. 2006 Oct;6(10):789-802. doi: 10.1038/nrc1977. Nat Rev Cancer. 2006. PMID: 16990856 Review.
Cited by
-
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.Int J Mol Sci. 2018 Nov 6;19(11):3480. doi: 10.3390/ijms19113480. Int J Mol Sci. 2018. PMID: 30404148 Free PMC article. Review.
-
A facile sonochemical protocol for synthesis of 3-amino- and 4-amino-1,2,4-triazole derived Schiff bases as potential antibacterial agents.PLoS One. 2020 Jun 4;15(6):e0229891. doi: 10.1371/journal.pone.0229891. eCollection 2020. PLoS One. 2020. Retraction in: PLoS One. 2020 Aug 20;15(8):e0238168. doi: 10.1371/journal.pone.0238168. PMID: 32497076 Free PMC article. Retracted.
-
In Vitro Anticancer Screening, Molecular Docking and Antimicrobial Studies of Triazole-Based Nickel(II) Metal Complexes.Molecules. 2022 Oct 3;27(19):6548. doi: 10.3390/molecules27196548. Molecules. 2022. PMID: 36235085 Free PMC article.
-
Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells.World J Gastroenterol. 2005 Sep 7;11(33):5156-61. doi: 10.3748/wjg.v11.i33.5156. World J Gastroenterol. 2005. PMID: 16127745 Free PMC article.
-
Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides.Nucleic Acids Res. 2006 Apr 5;34(6):1900-11. doi: 10.1093/nar/gkl126. Print 2006. Nucleic Acids Res. 2006. PMID: 16598074 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources